Begin main content

Vectibix for mCRC – Details

Project Number pCODR 10060
Brand Name Vectibix
Generic Name Panitumumab
Strength 20mg/mL (100mg vial)
Tumour Type Gastrointestinal
Indication Metastatic Colorectal Cancer
Funding Request For the treatment of patients with WT RAS mCRC in first line treatment setting in combination with FOLFOX
Review Status Notification to Implement Issued
Pre Noc Submission Yes
NOC Date August 31, 2015
Manufacturer Amgen Canada Inc.
Submitter Amgen Canada Inc.
Submission Date April 15, 2015
Submission Deemed Complete April 22, 2015
Submission Type New Indication
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ April 29, 2015
Check-point meeting July 6, 2015
pERC Meeting September 17, 2015
Initial Recommendation Issued October 1, 2015
Feedback Deadline ‡ October 16, 2015
pERC Reconsideration Meeting November 19, 2015
Final Recommendation Issued December 3, 2015
Notification to Implement Issued December 18, 2015

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.